Research Article

Investigating Celastrol’s Anti-DCM Targets and Mechanisms via Network Pharmacology and Experimental Validation

Rui Xi,1 Yongxin Wan,1 Lihong Yang,1 Jingying Zhang,1 Liu Yang,1 Shuai Yang,1 Rui Chai,1 Fengchen Mu,2 Qiting Sun,3 Rui Yan,1 Zhifang Wu1,4 and Sijin Li1,4

1Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
2Department of Vascular Medicine, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, China
3Department of Nuclear Medicine, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, China
4Molecular Imaging Precision Medical Collaborative Innovation Center, Shanxi Medical University, Taiyuan, Shanxi, China

Correspondence should be addressed to Zhifang Wu; wuzhifang01@163.com and Sijin Li; lisjm123@163.com

Received 25 April 2022; Accepted 31 May 2022; Published 5 July 2022

Academic Editor: Zhijun Liao

Copyright © 2022 Rui Xi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Purpose. DCM (diabetic cardiomyopathy), which may lead to significant complications including cardiovascular lesions, arrhythmia, and even heart failure, has a beginning element now known to be myocardial energy rebuilding. There are limited research on Celastrol’s ability to guard against this in the United States and elsewhere. Since it has not been known, whether Celastrol could reverse the early energy remodeling process, thus, it was hypothesized that triptolide Celastrol is suitable for the reversal of early myocardial energy remodeling in DCM. And our aim is to predict the targets and underlying mechanism of Celastrol in reversing the early energy remodeling for DCM.

Methods. Data from TCMSP and GEO databases were utilized to identify targets for Celastrol on DCM. The relationship between the major targets and conventional glycolipid metabolism was obtained with Spearman correlation analysis. Experiments on animals were conducted utilizing healthy control (HC), low-dose Celastrol interventions (CL), and no intervention groups (NC), all of which had 8 SD rats in each group. To study alterations in signaling molecules, RT-PCR was performed.

Results. There were 76 common targets and 5 major targets for Celastrol-DCM. Celastrol have been found to regulate AGE-RAGE, TNF, MAPK, TOLL-like receptors, insulin resistance, and other signaling pathways, and they are closely linked to adipocytokines, fatty acid metabolism, glycolipid biosynthesis, and glycosylphosphatidylinositol biosynthesis on DCM. These five major targets have been found to regulate these pathways. Experiments on rats indicated that P38 MAPK was considerably elevated in the cardiac tissue from rats in the CL and NC groups compared to the HC group, and the difference was statistically significant ($P < 0.01$). Significant differences were seen between the CL and NC groups in P38 MAPK levels, with a statistical significance level of less than 0.05. Conclusion. Celastrol may play a role in reversing energy remodeling, anti-inflammation, and oxidative stress via modulating p38 protein expression in the MAPK pathway, which have been shown in the treatment of DCM.

1. Introduction

DCM involves a range of changes caused by diabetes mellitus (DM) to the myocardial structure and function [1]. The increase of fatty acid-oxidation and decrease of glucose oxidation in ventricular myocytes are the significant characteristics of DCM energy rebuilding. In some research, it has been shown that myocardial energy restoration is conducive to enhancing DCM development [2–4]. As a leading cause of diabetes-related mortality, DCM can have a substantial impact on the well-being of patients [5, 6]. Cardiac remodeling and dysfunction may be alleviated by early intervention with the rebuilding of myocardial energy (changing the ratio of myocardial glucose to fatty acid metabolism) [7–10]. Besides, there are more and more studies confirming that the early intervention with DCM energy restoration plays an essential role in preventing myocardial remodeling and cardiac dysfunction [11, 12]. Celastrol, which can produce various biological effects, has been reportedly applied for the prevention and treatment of tumors, lupus erythematosus,
rheumatoid arthritis, etc. [13–15]. Additionally, Celastrol is regarded as having a massive potential to serve as a contemporary medicine for treatment by “CELL” due to its diverse effects [16]. However, there remains a lack of clarity on whether Celastrol can play a protective role in the early energy remodeling of DCM and its underlying mechanism. Besides, network pharmacology is a relatively new subject of study that links the disciplines like pharmacology, bioinformatics, and system biology. It provides an effective solution to revealing the mechanism of effect produced by those compounds used in traditional Chinese medicine. It entails an analysis as to the mechanism of medication-induced effects and the organisms in aggregate by establishing a “disease-target-drug” network. Thus, it is hypothesized that triptolid Celastrol is applicable to the reversal of early energy remodeling in DCM. This paper is purposed to predict the targets and underlying mechanism of Celastrol in reversing the early energy remodeling for DCM. So, network pharmacology concepts and methodologies were applied in this study to explore the key targets of Celastrol against DCM, as well as the pathways involved in the mechanism of action of DCM [17–19]. According to the relevant principles and methods of network pharmacology [17, 20], we not only analyzed the main targets of Celastrol on DCM but also applied the research methods of “Li et al.” to predict and analyze its enriched biological processes and signaling pathways [17]. Finally, during animal experiments, PCR technology was applied to confirm the content of specific molecular genes in individual signaling pathways (Figure 1).

2. Materials and Methods

2.1. Database and Software. Databases and software used in this study include TCMSP database (http://lsp.nwu.edu.cn/tcmsp.php), Swiss Target database (http://www.swisstargetprediction.ch/), Batman-TCM database (http://bionet.ncpsb.org/batman-tcm), DisGeNET database (https://www.disgenet.org/), OMIM database (https://omim.org/), GeneCard database (https://www.genecards.org/), GEO database (GSE4745) (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4745), R 3.6.1 software, Venny2.1 software (http://bioinfogp.cnb.csic.es/tools/venny/index.html), STRING online database 11.0 (https://string-db.org), and NetworkAnalyzer in the Cytoscape software (version 3.7.1).

2.2. Screening of Celastrol Effect Targets. Celastrol was retrieved from the TCMSP database, and DCM targets were retrieved from the Swiss Target database and the Batman-TCM database. Potential effective targets related to DCM were then identified using DisGeNET database, OMIM database, GeneCard database, and GEO database (GSE4745). Further, common targets of Celastrol and DCM were determined using a Venn diagram. STRING tool was used to construct PPI networks for targets of Celastrol and DCM, and visualization was done using Cytoscape 3.7.1. KEGG enrichment analysis was performed to explore signaling pathways of the drug and DCM that are implicated in energy reconstruction. The metabolic pathway level of each sample was quantified based on ssGSEA, and the relationship between major targets and energy metabolism was explored through Spearman correlation analysis. Experiments on animals were conducted to study alterations in signaling molecules.
TCM database. Gene names and ID corresponding to all drug targets were recorded for further network pharmacological data analysis.

2.3. **DCM Targets.** “Diabetic cardiomyopathy” was used as the keyword to retrieve target genes related to DCM from DisGeNET database, OMIM database, and GeneCard database. Retrieved data were sorted out and included in the GSE4745 differential gene data set. Redundant and duplicate targets were deleted.

2.4. **Screening of Drug-DCM Interactive Targets.** Venn diagram of Celastrol and DCM disease targets was constructed using Venny 2.1 online tool (http://bioinfogp.cnb.csic.es/tools/venn/index.html). Protein names of interactive targets were obtained then obtained from the Venn diagram.

2.5. **Construction of “Drug-Target-DCM” Network.** Major targets of Celastrol against DCM were explored using STRING online database (https://string-db.org), with a confidence score > 0.4 as the separating point standard. A network diagram of “drug-target-disease” interaction and PPI network was then constructed. Topological parameters in the network, such as median degree and maximum degree, were analyzed using NetworkAnalyzer in Cytoscape (version 3.7.1). Major targets were identified based on the degree. The upper limit of the range was the largest degree in the topological data, and the lower limit was twice the median value of the degree. The Cytoscape software was used for visualization of the PPI network.

2.6. **GO and KEGG Functional Annotation and Analysis.** Functional annotation of major targets was carried out using “ClusterProfiler,” R package, to comprehensively explore related function of these targets. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to explore the relevant functional categories. GO function analysis was mainly used to describe the function of major targets, including cell localization, molecular function, and biological process. KEGG enrichment analysis was used to explore enriched signaling pathways related to the common targets of Celastrol and DCM. GO and KEGG enrichment paths with P and q values less than 0.05 were considered as significant categories.

2.7. **Correlation Analysis between Target and Metabolic Pathway.** The metabolic path level of each sample was quantified using ssGSEA. Spearman correlation analysis was carried out to determine correlation between gene expression quantity and metabolic pathway.

2.8. **Validation of Animal Tests**

2.8.1. **Main Reagents and Instruments.** These are as follows: Streptozotocin (STZ), Sigma. Celastrol, Chengdu Destructive Biotechnology Co., and high-sugar and high-fat feed (58.8% nutrient rich base feed, 20% lard, 1% cholesterol, 0.2% bile salt, and 20% sugar), Nanjing Shengmin Research Animal Farm. Blood glucose meter and test strips, Stable type, were manufactured by China Sanuo Biosensing Co.

2.8.2. **Experimental Animals and Groups.** 16 DCM and 8 healthy control SD rats, male, 200-230 g, were kept in rat cages with a temperature range of 18-26°C, a relative humidity range of 40-70%, a noise level of less than 85 dB, and an ammonia content of less than 20 ppm. They were given a breather every 8-12 hours. Sixteen model rats were randomly assigned to the Cel low-dose group (CL) or the control group that received no treatment (NC). High-sugar, high-fat diets were given to 8 rats from each group. Modeling had been completed on day 1, and therefore, treatment could begin on day 2. For the HC group, the regular diet was maintained, whereas the CL group received 50 μg/kg of body weight per day. After 4 weeks of high sugar and fat diet, the rats in the NC group were given a lethal injection. All animal experiments involving rats were performed following the Principles of Laboratory Animal Care (Peoples Republic of China), and the animal protocols were approved by the Ethics Committee of Shanxi Medical University (No. SYDL2019002).

2.8.3. **Quantitative Real-Time Fluorescence PCR Assay (RT-PCR) for P38 MAPK Content.** A total of roughly 100 mg of fresh tissue was taken, frozen, and kept at -80°C. Total RNA was isolated from the obtained cardiac tissue using Trizol reagent (#15596-026, Ambion, California, USA) and kept at -80°C in the refrigerator as a backup. First-strand cDNA was synthesized from total RNA using 4× gDNA wiper mix (#R223-01, VAZYME, Nanjing, China). 5× HiScript II Select qRT SuperMix II (#R233-01, VAZYME, Nanjing, China) was used to detect amplification of specific PCR products according to the manufacturer’s instructions. It was done by electrophoresis with GelRed and DNA markers in GelRed, which resulted in separation of PCR products from each other. As a control, GAPDH was employed. The manufacturer’s instructions were followed for doing real-time quantitative PCR using SYBR Green Master Mix (#R223-01, VAZYME, Nanjing, China). Data were normalized based on β-actin mRNA levels. The final specific primer sequences (SANGON, Shanghai, China) are listed in Table 1 below.

2.9. **Statistical Analysis.** R was used to do network pharmacology data analysis (version 3.6). All statistical tests were two-sided, and P < 0.05 was deemed statistically significant in all cases. We conducted several basic tests and utilized the SPSS 26.0 statistical analysis software to analyze the data, with continuous variables reported in terms of mean ± standard deviation, while comparisons between two groups that satisfied the normality test were assessed by samples t. For numerous comparisons between groups that passed the homogeneity test for variances, one-way ANOVA was used. LSD-t was used for two comparisons between groups that had identical variances. When the variance normality and homogeneity tests were not fulfilled, nonparametric tests were used to compare data from different groups. The Kruskal-Wallis test may be used to compare two groups, and differences are regarded statistically significant if P < 0.05.
3. Results

3.1. Drug and DCM Target Prediction. A total of 161 targets associated with Celastrol were retrieved from the TCSMP database, the Swiss Target database, and the Batman database (Supplementary data 1). Differential genes of DCM were evaluated using the GSE4745 data set in the GEO database. The differential screening conditions were logFC > 1 and P < 0.05. A total of 59 differential genes were identified, including 35 upregulated genes and 24 downregulated genes (Supplementary Table 1). Targets related to DCM were explored using the DisGeNET database, OMIM database, and GeneCard database (relevance score > 5), and a total of 2075 targets related to DCM were retrieved (Supplementary data 2). Furthermore, the intersection of all targets was determined using a Venn diagram, and a total of 76 drug-DCM interactive targets were obtained (Figure 2, Supplementary Table 2). Pharmacological targets and function-related PPI networks of Celastrol on DCM were constructed.

3.2. Construction of PPI Network and Screening of Key Target Genes. A total of 76 Celastrol-DCM common targets were uploaded into the STRING database for PPI network analy-

| Gene       | Primer | Sequence (5′-3′) | PCR products |
|------------|--------|------------------|--------------|
| GAPDH      | Forward| ACAGCAACAGGGTGTTGGAC | 253 bp       |
|           | Reverse| TTTGAGGTGCCAGGAGACTT |              |
| p38 MAPK   | Forward| ATGTCGAGAGAGCCACGGTCTT | 188 bp       |

The primers were synthesized by Shanghai Sangon Biological Engineering Technology Company Limited.

Figure 2: Venn diagram of common targets of Celastrol and DCM. There were 161 targets of Celastrol that can prevent and treat disease, 2075 targets for the prevention and treatment of DCM, and 76 common targets for Celastrol and diabetic cardiomyopathy (DCM).

Figure 3: Relationship between the five key targets. Celastrol key targets against DCM were IL6, VEGFA, TNF, CASP3, and MAPK8.
sis. A median degree of 24.5, the maximum degree of 57, and a screening range of core gene connectivity of 49-57 were obtained. The analysis showed a total of five major targets of Celastrol on the DCM network, namely, IL6, VEGFA, TNF, CASP3, and MAPK8 (Figure 3, Supplementary Table 3).

3.3. GO Functional Enrichment Analysis. GO enrichment analysis of major targets was carried out using the R software, and data were presented as a histogram, bubble diagram, and chordal graph (Figure 4). Color-code in the histogram indicates the significance of the P value of the corresponding gene. Deep red color represents highly enriched genes (Figure 4(a)). The abscissa of the bubble diagram represents the percentage of genes. A larger circle represents a higher enrichment number, and deep red color implies that the expression level of the gene is significantly high (Figure 4(b)). GO enrichment analysis showed that five major targets are mainly involved in biological processes such as response to reactive oxygen species (ROS), peptidyl-serine phosphorylation, peptidyl-serine modification, lipopolysaccharide, molecules of bacterial origin, oxidative stress, and regulation of cell-cell adhesion, DNA-binding transcription factors, peptidyl-serine phosphorylation, and leukocyte migration (Supplementary Table 4).

3.4. KEGG Enrichment Analysis. The five major targets were identified through KEGG pathway analysis using the R software ClusterProfiler package. Previous studies report that pathways related to energy reconstruction are associated
with DCM including AGE-RAGE signaling pathway, TNF signaling pathway, MAPK signaling pathway, TOLL-like receptor, insulin resistance, and NOD-receptor signaling pathway (Figure 5, Supplementary Table 5).

3.5. Visualization of Drug and DCM Targets. The network visualization "Celastrol-target-DCM" interaction diagram (Figure 6) was generated using the Cytoscape software. The network showed that Celastrol regulates DCM by modulating five major targets, namely, VEGFA, MAPK8, IL6, CASP3, and TNF. This finding implies that Celastrol is implicated in abrogation of the pathogenesis of DCM.

3.6. Analysis of the Relationship between Targets and Metabolic Pathways. Spearman correlation analysis showed that the five major targets had different degrees of correlation with disease energy metabolism. Specific manifestations observed were as follows: VEGFA was correlated with adipocytokines, lipid metabolism, fatty acid metabolism, glycolipid biosynthesis, glycosylphosphatidylinositol biosynthesis, and insulin signaling pathway whereas TNF was correlated with adipocytokines, lipid metabolism, and insulin signaling pathway. In addition, MAPK8 was correlated with fatty acid metabolism and glycolipid biosynthesis; IL6 was correlated with peroxidase activity whereas CASP3 was correlated with

![Figure 5: KEGG enrichment analysis for five key targets implicated in the role of Celastrol in DCM. Top 30 signaling pathway with P < 0.05 were identified using R packages. (a) Histograms, (b) bubble diagram, and (c) chordal graph showing top 30 enriched signaling pathways. The x-axis represents enriched gene count or ratio, and y-axis represents the different biological processes. Color intensity represents adjusted P value.](image-url)
lipid metabolism, fatty acid metabolism, and glycolipid biosynthesis (Figure 7).

3.7. Experimental Validation. RT-PCR analysis revealed that the ratio of P38 MAPK/GAPDHA was significantly increased in the DCM group compared with the HC group \((1.71 \pm 0.08 \text{ vs. } 0.61 \pm 0.43, P < 0.01)\), whereas the ratio of P38 MAPK/GAPDHA was significantly decreased in the CL group compared with the DCM group after Celastrol administration \((0.67 \pm 0.49 \text{ vs. } 1.71 \pm 0.08, P < 0.01)\) (Figure 8). This indicates that low-dose Celastrol may also have a modest effect on the expression of the P38 MAPK gene in the myocardial tissue of DCM to some extent, suggesting a novel target for intervention in the energetic remodeling of DCM and progression of the disease.

4. Discussion

Diabetes mellitus has now become a severe public health concern worldwide [20], with the total cases of diabetics estimated to reach 629 million by 2045 [21]. DCM, as one of the primary complications and causes of mortality, was initially postulated in 1972 [22] and has since become a focus of clinical and fundamental research, attracting the attention of clinicians and researchers [23]. Furthermore, it has been confirmed by both clinical and experimental studies that various pathophysiological changes can result from myocardial energy remodeling, reduced sugar and lactate metabolism, and increased lipid metabolism, such as oxidative stress, apoptosis, endothelial dysfunction, increased inflammatory response, blood hypercoagulation, and myocardial...
fibrosis, as well as the damage caused to mitochondria, cells, and microcirculation, interstitial fibrosis, and the structural and functional changes in the myocardium. It is manifested as the catastrophic repercussions like microvascular and macrovascular cardiac issues, cardiac arrhythmias, cardiac insufficiency, and even heart failure, all of which are the major causes of mortality and have a significant impact on the quality of life for diabetics [6, 11, 24]. At present, there are still no definitive diagnostic markers or preventative measures for DCM [25]. As one of the main components of Tripterygium wilfordii, Celastrol has been recently reported in some studies to prevent and treat diabetic nephropathy, insulin resistance, and obesity [26–31]. However, there is still no clarity provided on whether Celastrol has a protective effect on early energy remodeling in DCM.

In addition, network pharmacology, as an emerging drug research discipline that involves cell biology, pharmacology, and systems biology, was first proposed by Chinese scholars in 2007 and then became a research hotspot in 2017. The World Federation of Chinese Medicine Societies approved and published the “Guidelines for Network Pharmacology Evaluation Methods.”

On the basis of what has been discussed above, a “drug-target-disease” coexpression network was established by applying network pharmacology and taking bioinformatics approaches, so as to predict the key targets of Celastrol for the treatment of DCM, with five significant targets explored. According to the additional enrichment study of DCM through GO and KEGG, the primary signaling pathways involved in its regulation include AGE-RAGE, TNF, MAPK, TOLL-like receptor, insulin resistance, and the NOD-receptor signaling pathway. Therefore, Celastrol is expected to produce a protective impact on DCM through a variety of signaling mechanisms. Both glucolipid metabolism and cardiomyocyte contractile performance can be affected by insulin resistance [32], as demonstrated by the interaction with MAPK and PI3-K signaling mechanisms. The metabolic actions of insulin are largely dependent on the role of PI3-K in regulating glucose, lipid, and protein metabolism [33, 34]. As a “transmitter” in the signaling network of eukaryotic organisms, MAPK is involved in a variety of signaling pathways, including those for cell proliferation, stress, inflammation, differentiation, functional synchronization, transformation, and death [35]. As one of the most significant components of inflammatory and oxidative stress signaling pathways, MAPK phosphorylation is presumed to play a role in cell proliferation, survival, necrosis, and other pathological events [6]. Mitogen-activated protein kinase p38 (P38 MAPK), which is a critical molecule in the MAPK signaling pathway [36], plays a critical role in energy remodeling in T2DM, IR, and survival status of pancreatic β-cells. Triggered by elevated glucose, free fatty acids, and inflammatory substances, it may contribute to the mitogenic and growth-promoting activities of insulin. DCM microangiopathy, myocardial interstitial fibrosis, and myocardial hypertrophy all rely on it for development.

It has been shown in some studies that even the minimum dosage of Celastrol may significantly reduce the damage caused by diabetes-induced nephropathy. In order to exert its effects, Celastrol is involved to modify the MAPK/NF-B signaling pathway [37]. Under the regulation of DCM, the MAPK signaling pathway plays a critical role [38, 39]. At the same time, the MAPK/NF-κB signaling pathway is also crucial to the regulation of energy metabolism in DCM. Caused by abnormal glucose uptake, cardiac dysfunction is associated with the upregulation of p38 MAPK and the increase of ROS. The upregulation of ROS in diabetes can lead to the activation of p38 MAPK, which reduces the activity of insulin receptors, thus affecting the synthesis and expression of glucose transporters in cardiomyocytes through phosphatidylinositol 3. This results in myocardial mitochondrial dysfunction and the reduced efficiency of myocardial substrate production [38]. In the model rats (CL and NC groups), P38 MAPK expression was found much higher than in the HC group, indicating that P38 MAPK can be implicated in the development of DCM illness. Following the administration of Celastrol, however, P38 MAPK expression declined significantly. P38 MAPK activity was suppressed in comparison with baseline, while myocardial disruption, cell swelling, and fibrosis were alleviated, indicating the potential of Celastrol to protect against DCM by inhibiting P38 MAPK activation and acting on the insulin resistance pathway.

5. Conclusions

We examined the major targets and potential molecular mechanisms of Celastrol’s reverse regulation of energetic remodeling of DCM from a variety of perspectives in this study and concluded that Celastrol may exert protective effects on DCM via a variety of signaling pathways. By modulating insulin resistance signaling, P38 MAPK may have a complicated regulatory function in numerous areas of energy remodeling and inflammation in DCM. This gives
theoretical justification for the innovative use of Celastrol in DCM and directs future research.

6. Limitations

The limitations of this study include the small sample size and the lack of experimental studies on activation and inhibition at the cellular level for the specific mechanism of Celastrol’s reverse regulation of early energy remodeling in DCM.

Data Availability

The data used for the study are included within the article and the supplementary files.

Conflicts of Interest

Authors confirm that there is no conflicts of interest.

Supplementary Materials

Supplementary 1. Supplementary Table 1: the differential genes of DCM.

Supplementary 2. Supplementary Table 2: Celastrol-DCM interactive targets.

Supplementary 3. Supplementary Table 3: PPI network analysis for Celastrol-DCM major targets.

Supplementary 4. Supplementary Table 4: the GO biological process of the major targets.

Supplementary 5. Supplementary Table 5: the KEGG signal pathways of the major targets.

Supplementary 6. Supplementary data 1: the details on Celastrol-related targets from the TCSMP database, the Swiss Target database, and the Batman database.

Supplementary 7. Supplementary data 2: the details on DCM-related targets from the DisGeNET database, OMIM database, and GeneCard database (relevance score > 5).

References

[1] S. Nunes, E. Soares, J. Fernandes et al., “Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide overexpression seems to be the best marker,” Cardiovascular Diabetology, vol. 12, no. 1, 2013.

[2] A. R. Wende, J. C. Schell, C. M. Ha et al., “Maintaining myocardial glucose utilization in diabetic cardiomyopathy accelerates mitochondrial dysfunction,” Diabetes, vol. 69, no. 10, pp. 2094–2111, 2020.

[3] S. Battault, E. Renguet, A. Van Steenberghe, S. Horman, C. Beaulye, and L. Bertrand, “Myocardial glucotoxicity: mMechanisms and potential therapeutic targets,” Archives of Cardiovascular Diseases, vol. 113, no. 11, pp. 736–748, 2020.

[4] N. Freemantle, N. Danchin, F. Calvi-Gries, M. Vincent, and P. D. Home, “Relationship of glycemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin,” Diabetes, Obesity & Metabolism, vol. 18, no. 2, pp. 152–158, 2016.

[5] J. M. Gao, B. Hu, and E. Shen, “Research progress on the association between myocardial fibroblast transdifferentiation and diabetic cardiomyopathy,” Zhonghua Xin Xue Guan Bing Za Zhi, vol. 48, no. 10, pp. 885–889, 2020.

[6] I. Evangelista, R. Nuti, T. Picchioni, F. Dotta, and A. Palazzuoli, “Molecular dysfunction and phenotypic derangement in diabetic cardiomyopathy,” International Journal of Molecular Sciences, vol. 20, no. 13, p. 3264, 2019.

[7] D. J. Gorski, A. Petz, C. Reichert, S. Twarock, M. Grandch, and J. W. Fischer, “Cardiac fibroblast activation and hyaluronan synthesis in response to hyperglycemia and diet-induced insulin resistance,” Scientific Reports, vol. 9, no. 1, p. 1827, 2019.

[8] J. Kalra, S. B. Mangali, D. Dasari et al., “SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy,” Fundamentals & Clinical Pharmacology, vol. 34, no. 2, pp. 173–188, 2020.

[9] K. Khunti, M. Kosiborod, and K. K. Ray, “Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: time to overcome multifactorial therapeutic inertia?,” Diabetes, Obesity & Metabolism, vol. 20, no. 6, pp. 1337–1341, 2018.

[10] R. Roussel, P. G. Steg, K. Mohammedi, M. Marre, and L. Potier, “Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: a perspective on glucose-lowering interventions,” Diabetes, Obesity & Metabolism, vol. 20, no. 2, pp. 238–244, 2018.

[11] G. Jia, A. Whaley-Connell, and J. R. Sowers, “Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease,” Diabetologia, vol. 61, no. 1, pp. 21–28, 2018.

[12] B. Y. Peng, N. K. Dubey, V. K. Mishra et al., “Addressing stem cell therapeutic approaches in pathobiology of diabetes and its complications,” Journal of Diabetes Research, vol. 2018, Article ID 7806435, 16 pages, 2018.

[13] T. S. Chang, T. Y. Wang, C. M. Chiang et al., “Biotransformation of celastrol to a novel, well-soluble, low-toxic and anti-oxidative celastrol-29-O-β-glucoside by Bbacillus glycosyltransferases,” Journal of Bioscience and Bioengineering, vol. 131, no. 2, pp. 176–182, 2021.

[14] L. Xu, W. Zhao, D. Wang, and X. Ma, “Chinese medicine in the battle against obesity and metabolic diseases,” Frontiers in Physiology, vol. 9, p. 850, 2018.

[15] R. Cascão, J. E. Fonseca, and L. F. Moita, “Celastrol: a spectrum of treatment opportunities in chronic diseases,” Frontiers in Medicine, vol. 4, p. 69, 2017.

[16] J. Liu, J. Lee, M. A. Salazar Hernandez, R. Mazitschek, and U. Ozcan, “Treatment of obesity with celastrol,” Cell, vol. 161, no. 5, pp. 999–1011, 2015.

[17] R. Li, C. Guo, Y. Li, Z. Qin, and W. Huang, “Therapeutic targets and signaling mechanisms of vitamin C activity against sepsis: a bioinformatics study,” Briefings in Bioinformatics, vol. 22, no. 3, 2021.

[18] C. Ma, T. Xu, X. Sun et al., “Network pharmacology and bioinformatics approach reveals the therapeutic mechanism of action of baicalein in hepatocellular carcinoma,” Evidence-based Complementary and Alternative Medicine: Ecam, vol. 2019, article 7518374, 15 pages, 2019.

[19] T. Zhang, L. Pan, Y. Cao, N. Liu, W. Wei, and H. Li, “Identifying the mechanisms and molecular targets of Yizhiqingxin formula on Alzheimer’s disease: coupling network pharmacology with GEO database,” Pharmacogenomics and Personalized Medicine, vol. 13, pp. 487–502, 2020.
[20] M. Verboven, D. Deluyker, V. Ferferieva et al., “Western diet given to healthy rats mimics the human phenotype of diabetic cardiomyopathy,” *The Journal of Nutritional Biochemistry*, vol. 61, pp. 140–146, 2018.

[21] J. B. Cole and J. C. Florez, “Genetics of diabetes mellitus and diabetes complications,” *Nature Reviews. Nephrology*, vol. 16, no. 7, pp. 377–390, 2020.

[22] S. Rubler, J. Dlugash, Y. Z. Yuceoglu, T. Kumral, A. W. Branwood, and A. Grishman, “New type of cardiomyopathy associated with diabetic glomerulosclerosis,” *The American Journal of Cardiology*, vol. 30, no. 6, pp. 595–602, 1972.

[23] W. S. Lee and J. Kim, “Diabetic cardiomyopathy: where we are and where we are going,” *The Korean Journal of Internal Medicine*, vol. 32, no. 3, pp. 404–421, 2017.

[24] S. P. Levick and A. Widiapradja, “The diabetic cardiac fibroblast: mechanisms underlying phenotype and function,” *International Journal of Molecular Sciences*, vol. 21, no. 3, p. 970, 2020.

[25] S. Paolillo, F. Marsico, M. Prastaro et al., “Diabetic cardiomyopathy: definition, diagnosis, and therapeutic implications,” *Heart Failure Clinics*, vol. 15, no. 3, pp. 341–347, 2019.

[26] X. Zhan, C. Yan, Y. Chen et al., “Celastrol antagonizes high glucose-evoked podocyte injury, inflammation and insulin resistance by restoring the HO-1-mediated autophagy pathway,” *Molecular Immunology*, vol. 104, pp. 61–68, 2018.

[27] Y. Nie, C. Fu, H. Zhang et al., “Celastrol slows the progression of early diabetic nephropathy in rats via the PI3K/AKT pathway,” *BMC Complementary Medicine and Therapies*, vol. 20, no. 1, p. 321, 2020.

[28] W. Hu, L. Wang, G. Du et al., “Effects of microbiota on the treatment of obesity with the natural product Celastrol in rats,” *Diabetes & Metabolism Journal*, vol. 44, no. 5, pp. 747–763, 2020.

[29] K. Chellappa, I. J. Perron, N. Naidoo, and J. A. Baur, “The leptin sensitiser celastrol reduces age-associated obesity and modulates behavioral rhythms,” *Aging Cell*, vol. 18, no. 3, article e12874, 2019.

[30] C. J. Zhang, N. Zhu, J. Long et al., “Celastrol induces lipophagy via the LXRA/ABCA1 pathway in clear cell renal cell carcinoma,” *Acta Pharmacologica Sinica*, vol. 42, no. 9, pp. 1472–1485, 2021.

[31] M. H. Abu Bakar, K. A. Shariff, J. S. Tan, and L. K. Lee, “Celastrol attenuates inflammatory responses in adipose tissues and improves skeletal muscle mitochondrial functions in high fat diet-induced obese rats via upregulation of AMPK/SIRT1 signaling pathways,” *European Journal of Pharmacology*, vol. 883, article 173371, 2020.

[32] S. Guo, “Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms,” *The Journal of Endocrinology*, vol. 220, no. 2, pp. T1–T23, 2014.

[33] B. P. Kok and D. N. Brindley, “Myocardial fatty acid metabolism and lipotoxicity in the setting of insulin resistance,” *Heart Failure Clinics*, vol. 8, no. 4, pp. 643–661, 2012.

[34] D. K. Posa and S. P. Baba, “Intracellular pH regulation of skeletal muscle in the milieu of insulin signaling,” *Nutrients*, vol. 12, no. 10, p. 2910, 2020.

[35] Y. Guo, X. Zhuang, Z. Huang et al., “Klotho protects the heart from hyperglycemia-induced injury by inactivating ROS and NF-κB-mediated inflammation both in vitro and in vivo.”